Prospective, multicentre trial evaluating FET-PET in Glioblastoma

The FIG trial is investigating how the addition of FET-PET imaging to standard MRI imaging affects radiation target volume delineation and treatment planning for Glioblastoma, as well as determining the accuracy and management impact of FET-PET in distinguishing pseudoprogression from true tumour progression and / or tumour recurrence.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

COGNO, ARTnet, ONJCRI

Accrual Target

310

Trial Chairperson

Prof Andrew Scott, Olivia Newton-John Cancer Research Institute (ONJCRI) / The Austin Health, VIC, Australia

Prof Eng-Siew Koh, Liverpool Hospital, NSW, Australia

Trial Contact

FIG@trog.com.au

Clinical Trial Registration

Related Post

17 November, 2026

Every kilometre counts: TROG supporters go the distance for cancer research

LATEST NEWS: 17 November 2026 From early morning walks

10 November, 2026

Golfers tee off for annual TROG fundraiser

LATEST NEWS: 10 November 2026 The Myall Coast Veteran